SAM
CMPX icon

Smartleaf Asset Management’s Compass Therapeutics CMPX Stock Holding History

Smartleaf Asset Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$352 Hold
69
– – ﹤0.01% 3272
2025
Q4 		$371 Buy
+69
New +$319 ﹤0.01% 3296

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Smartleaf Asset Management's CMPX Position: Q1 2026 in Review

Smartleaf Asset Management held its Compass Therapeutics (CMPX) position steady in Q1 2026 at 69 shares worth $352. The position accounts for ﹤0.01% of the portfolio, ranked #3272.

Smartleaf Asset Management first reported a position in CMPX in Q4 2025 and has held it in 2 quarters since. The position peaked at $371 in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Smartleaf Asset Management held 69 shares of Compass Therapeutics worth $352 as of Q1 2026.
  • Smartleaf Asset Management left its Compass Therapeutics share count unchanged in Q1 2026.
  • Compass Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #3272 holding.
  • Smartleaf Asset Management first reported a position in Compass Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Smartleaf Asset Management's Compass Therapeutics position peaked at $371 in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.